Phase II trial of 5-fluorouracil, leucovorin, interferon-α-2a, and cisplatin as neoadjuvant chemotherapy for locally advanced esophageal carcinoma

✍ Scribed by Barbara K. Temeck; James E. Liebmann; Christopher Theodossiou; Seth M. Steinberg; John A. Cook; David C. Metz; Thomas H. Shawker; Carmen J. Allegra; Angelo Russo; Harvey I. Pass

• Publisher: John Wiley and Sons
• Year: 1996
• Tongue: English
• Weight: 635 KB
• Volume: 77
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/(sici)1097-0142(19960615)77:12<2432::aid-cncr3>3.0.co;2-o

✦ Synopsis

BACKGROUND.

Most patients with esophageal carcinoma present with locally advanced disease and a poor prognosis. Surgery or radiation provides palliation for locally advanced esophageal carcinoma. The role of neoadjuvant therapy remains to be defined. We administered neoadjuvant chemotherapy consisting of 5-fluorouracil(5-FU), leucovorin, interferon-a-2a, and ciplastin to 11 patients with locally advanced disease.

METHODS.

Eleven patients with squamous cell or adenocarcinoma of the esophagus were treated preoperatively with two to three cycles of combination chemotherapy. Nine patients underwent resection with curative intent.

RESULTS.

Six patients received three cycles of chemotherapy, and five received two. Dose reduction was necessary for two patients. One patient achieved a pathologic complete response, histologically confirmed. Of the eleven patients, two did not undergo surgery because of progressive disease during chemotherapy. Seven of the 9 patients relapsed after surgery and 2 have been disease free for 27 months.